📰 Weekly Medical Innovation Digest
October 28 – November 3, 2025
AI in Healthcare
Gene Therapy
Radioligand Theranostics
Insights & Perspective
Milestones
🤖 Artificial Intelligence in Healthcare
- Channel 4's Arti: UK's first AI news presenter launched, stirring up more existential dread among the BBC's human anchors. Source
- OpenAI's Atlas Browser: Directly challenges Google, deeply integrated with LLM-based search and research tools. Source
- MaLMIC Forum (Oct 31): Machine learning for multimodal brain imaging and clinical translation goes mainstream at MGH. Source
- MICCAI 2025: Swiss teams sweep 3 top competitions with self-supervised learning for medical imaging and segmentation. Source
- Stanford Virtual Scientist Lab: AI agents autonomously solve biological research problems, now with snarky commentary module. Source
- Isomorphic Labs: AI-designed CRISPR drugs enter human trials. Source
🧬 Gene Therapy Breakthroughs
- Retron Multi-Mutation Editing (Oct 25): Simultaneous correction of multiple disease mutations in vivo. Source
- ADA-SCID Safety Study: 100% OS, >95% cured in 7.5-year pediatric gene therapy cohort. Source
- UCD-NIBRT Manufacturing: €2M invested to slash gene therapy production costs and improve scalability. Source
- Eli Lilly/Adverum Acquisition: Major gene therapy pipeline expansion. Source
- Immusoft Fast Track: FDA accepts expedited pathway for neural-centric gene delivery. Source
- Lexeo FDA Accelerated Pathway: New gene therapy receives regulatory boost for cardiac indication. Source
| Trial/Company | Status | Notes |
|---|---|---|
| Retron Multi-Mutation | Preclinical | Mice & primate models, multi-locus efficacy |
| ADA-SCID (Europe) | Phase III | First 7.5yr cohort, pediatric population |
| Immusoft Neural Gene | FDA Fast Track | MPS1, neural disease focus |
☢️ Radioligand Theranostics
- Pluvicto in Early Prostate Cancer: PSMAddition Phase III: 28% boost in progression-free survival (PFS) in hormone-sensitive PCa. Source
- LUNAR Trial: PSMA RLT + XRT: 17.6 vs 7.4 months PFS (UCLA, ASTRO 2025). Source
- Mayo Clinic Alpha-RPT: First-in-human GPC3-targeted alpha-emitter for HCC, initial patients dosed. Source
- Clarity Pharmaceuticals: Pan-cancer FAP-targeting radioligand, expanding beyond prostate. Source
- OECD-NEA RLT Infrastructure: Global survey on supply/demand gaps and regulatory frustration. Source
| Program | Indication | PFS Benefit |
|---|---|---|
| Pluvicto (PSMAddition) | Hormone-sensitive PCa | 28% ↑ |
| LUNAR Trial | Metastatic PCa | +10.2 months |
| GPC3 Alpha-RPT | Hepatocellular Carcinoma | First-in-human, early data |
💡 Insights & Perspective
- AI now acts as both assistant and autonomous research partner (cue human existential crisis and job security queries).
- Gene therapy moves beyond ultra-rare to common disorders—finally, an excuse for investors to pretend they understand N-of-1 studies.
- Theranostics rapidly expands past PSMA-prostate to pan-cancer, multi-indication approaches.
- Emerging supply chain bottlenecks (Lu-177, Ac-225 isotopes), workforce development, and global equity issues—because nothing says "innovation" like regulatory migraine.
📌 In Case You Missed It
- Casgevy (CRISPR sickle cell cure) receives NHS/Walgreens rollout.
- Personalized CRISPR infant therapy crushes N=1 records in Boston.
- Allogene CAR-T kidney cancer trial hits durable CR.
- FDA boosts “Agentic AI” review path for digital biologicals.
Contact your local medical director for advice, existential comfort, or Pluvicto memes.